4 Clinical Particulars

Save this PDF as:
 WORD  PNG  TXT  JPG

Size: px
Start display at page:

Download "4 Clinical Particulars"

Transcription

1 SUMMARY OF PRODUCT CHARACTERISTICS 1 Name of the Medicinal Product Procyclidine Syrup 5mg/5ml 2. Qualitative and Quantitative Composition Each 5ml dose contains 5mg Procyclidine Hydrochloride BP. 3. Pharmaceutical Form Syrup 4 Clinical Particulars 4.1 Therapeutic indications Procyclidine is indicated in all forms of Parkinson s disease: idiopathic (paralysis agitans), postencephalitic and arteriosclerotic. Symptoms often responding well to Procyclidine include: rigidity, akinesia, tremor, speech and writing difficulties, gait, sialorrhoea and drooling, sweating, oculogyric crises and depressed mood. Tardive dyskinesia is not improved by Procyclidine and may be made worse. Procyclidine is also used to control troublesome extrapyramidal symptoms induced by neuroleptic drugs including pseudo-parkinsonism, acute dystonic reactions and akathisia Posology and Method of Administration For oral administration only. Adults Only: All forms of Parkinsonism Treatment is usually started at 2.5mg three times a day, increasing by 2.5 to 5mg daily at intervals of two or three days until the optimum clinical response

2 is achieved. The usual maximum total daily dose is 30mg. However, at the discretion of the attending physician where appropriate this total may be as high as 60mg. Drug induced Parkinsonism-like symptoms As above but the daily dosage used in the control of neuroleptic-induced extrapyramidal symptoms is usually not more than 20mg daily. After a period of 3 to 4 months Procyclidine should be stopped and the patient observed to see if the neuroleptic-induced extrapyramidal symptoms recur. Cessation of treatment periodically is to be recommended even in patients who appear to require the drug for longer periods. Elderly: Elderly patients are more sensitive to anticholinergics, and a reduced dose may be required. Children: Not recommended Avoid abrupt discontinuation of treatment. When changing from one drug to another, withdraw the one in small amounts whilst gradually increasing the dose of the other. Procyclidine tablets may be given with other drugs employed for the relief of parkinsonism e.g. other antimuscarinic drugs, levodopa and amantadine; dose reduction may be required Contra-indications Procyclidine is contra-indicated in patients with: Untreated urinary retention, closed angle glaucoma and gastrointestinal obstruction Special Warnings and Precautions for Use Since treatment is to be continued for an indefinite period, the patient should be carefully supervised over the long term. Incipient glaucoma may be precipitated by Procyclidine. Caution should be exercised in patients with obstructive disease of the gastrointestinal tract, those with urinary symptoms associated with prostatic hypertrophy and in hepatic and renal impairment, and those with hypertension and cardiac disorders. In a proportion of patients undergoing neuroleptic treatment, tardive dyskinesias will occur. While anticholinergic agents do not cause this

3 syndrome, when given in combination with neuroleptics they may reduce the threshold at which dyskinesias appear in patients predisposed to this abnormality. In such individuals subsequent adjustment of neuroleptic therapy is indicated Interactions with other Medicaments and other forms of Interaction Concurrent use of Procyclidine with drugs possessing anticholinergic effects increases the side effects such as dry mouth, urine retention and constipation, concomitant use can lead to confusion in the elderly. Such drugs include antidepressants (e.g. amitriptyline), phenothiazines (e.g. thioridazine), amantadine and disopyramide. The absorption of ketoconazole may be reduced by concomitant administration of Procyclidine. Concurrent use of Procyclidine with antihistamines however can increase the anticholinergic side-effects Pregnancy and Lactation The safety of using Procyclidine during pregnancy has not been established. However, extensive clinical use has not given any evidence that it in any way compromises the normal course of pregnancy. No data are available on the excretion of this drug in breast milk Effects on Ability to Drive and Use Machines May effect performance of skilled tasks e.g. driving therefore the patient should be warned Undesirable Effects The main side-effects are those to be expected from any anticholinergic agent: dry mouth, blurring of vision and constipation are most commonly recorded. Less commonly tachycardia, hypersensitivity, nervousness and with high doses dizziness, mental confusion and hallucinations may occur. The unwanted anticholinergic effects are easily reversed by reducing the dosage. In rare instances Procyclidine administered for the treatment of neurolepticinduced symptoms was associated with an apparent worsening of the patient s state.

4 4.9. Overdose Toxic doses result in tachycardia, rapid respiration, hyperpyrexia and CNS stimulation marked by restlessness, confusion, excitement, paranoid and psychotic reactions, hallucination and delirium and occasionally seizures or convulsions. A rash may appear on the face and upper trunk. In severe intoxication central stimulation may give way to CNS depression, coma, circulatory and respiratory failure and death. Treatment entails gastric lavage, emetic and high enema as there is no specific antidote. General supportive treatment should be carried out. Cold compresses and extra fluid are advised. Atropine antagonists may be useful. 5 Pharmacological Properties 5.1 Pharmacodynamic properties Procyclidine is a synthetic anticholinergic agent which blocks the excitatory effects of acetylcholine at the muscarinic receptor Pharmacokinetic Properties Procyclidine is adequately absorbed from the gastro-intestinal tract and disappears rapidly from the tissues. After oral dosing the mean values for volume of distribution, total body clearance and plasma elimination half-life of Procyclidine were of the order of 1 litre/kg, 68ml/min and 12 hours respectively Preclinical Safety Data There are no preclinical safety data of relevance to the prescriber which are additional to those already included in other sections of the SPC. 6 Pharmaceutical Particulars 6.1 List of excipients The syrup contains Sorbitol Solution (70%) BP, Sucrose BP, Raspberry Flavour (PPF 31/78/360), Nipasept Sodium, Potassium Sorbate BP, Cetamacrogol 1000 BP, Trisodium Citrate EP, Citric Acid Monohydrate EP and Deionised Water.

5 6.2. Incompatibilities None known Shelf Life 36 months Special Precautions for Storage Store in a cool, dark place, not exceeding 25 C Nature and Contents of Container Amber glass winchester with ropp aluminium closure with steran-lined wad in packs of 200ml Instruction for Use/Handling None. Administrative Data 7. Marketing Authorisation Holder Generics [UK] Ltd Station Close Potters Bar Hertfordshire EN6 1TL 8. Marketing Authorisation Number PL 04569/0124

6 9. Date of First Authorisation/Renewal of the Authorisation Date MA Granted: 07 March 1986 Last Renewal Date: 15 December Date of (Partial) Revision of the Text July 1999

2 QUALITATIVE AND QUANTITATIVE COMPOSITION

2 QUALITATIVE AND QUANTITATIVE COMPOSITION SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Trihexyphenidyl 2mg Tablets BP 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 2 mg of trihexyphenidyl hydrochloride BP

More information

White, circular, biconvex, uncoated tablets with a score line on one side, plain on the other.

White, circular, biconvex, uncoated tablets with a score line on one side, plain on the other. Nausicalm Cyclizine hydrochloride Ph. Eur. 50 mg Presentation White, circular, biconvex, uncoated tablets with a score line on one side, plain on the other. Uses Actions The active ingredient-cyclizine

More information

DESCRIPTION Benztropine mesylate, USP is a synthetic compound containing structural features found in atropine and diphenhydramine.

DESCRIPTION Benztropine mesylate, USP is a synthetic compound containing structural features found in atropine and diphenhydramine. DESCRIPTION Benztropine mesylate, USP is a synthetic compound containing structural features found in atropine and diphenhydramine. It is designated chemically as 3 -(Diphenylmethoxy)-1 H,5 H-tropane methanesulfonate.

More information

COGENTIN Injection. (benztropine mesylate)

COGENTIN Injection. (benztropine mesylate) COGENTIN Injection (benztropine mesylate) NAME OF THE MEDICINE Benztropine mesylate is a synthetic compound resulting from the combination of the active portions of atropine and diphenhydramine. Chemical

More information

BENZTROP 2 mg tablets are round, flat-faced, cross-scored on one side and embossed PMS- 2 on the other side.

BENZTROP 2 mg tablets are round, flat-faced, cross-scored on one side and embossed PMS- 2 on the other side. Benztrop Benzatropine mesilate 2 mg tablets Presentation BENZTROP 2 mg tablets are round, flat-faced, cross-scored on one side and embossed PMS- 2 on the other side. Uses Actions Benzatropine is a centrally

More information

VISTARIL (hydroxyzine pamoate) Capsules and Oral Suspension

VISTARIL (hydroxyzine pamoate) Capsules and Oral Suspension VISTARIL (hydroxyzine pamoate) Capsules and Oral Suspension DESCRIPTION Hydroxyzine pamoate is designated chemically as 1-(p-chlorobenzhydryl) 4- [2-(2-hydroxyethoxy) ethyl] diethylenediamine salt of 1,1

More information

SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT 2 QUALITATIVE AND QUANTITATIVE COMPOSITION

SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT 2 QUALITATIVE AND QUANTITATIVE COMPOSITION SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Diazepam Tablets BP 2mg 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Diazepam BP 2.00mg 3 PHARMACEUTICAL FORM Tablet 4. CLINICAL PARTICULARS

More information

Summary of Product Characteristics

Summary of Product Characteristics 1 NAME OF THE MEDICINAL PRODUCT Librium 10mg Hard capsule Summary of Product Characteristics 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each capsule contains 10 mg of chlordiazepoxide hydrochloride. Excipients:

More information

SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT 2 QUALITATIVE AND QUANTITATIVE COMPOSITION

SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT 2 QUALITATIVE AND QUANTITATIVE COMPOSITION SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Methadone 10mg/ml Injection / Physeptone 10mg/ml Injection 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Contains: Methadone Hydrochloride

More information

New Zealand Data Sheet

New Zealand Data Sheet MESTINON Pyridostigmine bromide Presentation New Zealand Data Sheet 60mg tablet: round, flat-faced, white tablets engraved "Mestinon 60" on outer perimeter and "V" in the centre, with a quadrisect score

More information

Anti-Parkinsonism Drugs

Anti-Parkinsonism Drugs Anti-Parkinsonism Drugs Pharma Team 429 Fahad Alrumaih Ibrahim Alshiddi Sultan Alsalem Ismail Raslan Suhail Asiri Parkinsonism - Could be: primary [idiopathic] or secondary [viral infection or drug induced

More information

Public Assessment Report. Loperamide 2mg Capsules. Loperamide hydrochloride PL 31308/ Max Remedies Ltd. Table of Contents

Public Assessment Report. Loperamide 2mg Capsules. Loperamide hydrochloride PL 31308/ Max Remedies Ltd. Table of Contents Public Assessment Report Loperamide 2mg Capsules Loperamide hydrochloride PL 31308/0002-3 Max Remedies Ltd Table of Contents Page Lay Summary 2 Scientific Discussion 3 Overall Conclusion And Risk Benefit/Analysis

More information

Mucodyne-Clear 250 mg/5 ml Syrup PL 04425/0665

Mucodyne-Clear 250 mg/5 ml Syrup PL 04425/0665 Mucodyne-Clear 250 mg/5 ml Syrup PL 04425/0665 UKPAR TABLE OF CONTENTS Lay summary Page 2 Scientific discussion Page 3 Steps taken for assessment Page 9 Summary of product characteristics Page 10 Patient

More information

Chapter 18 Drugs Used for Psychoses Learning Objectives Identify signs and symptoms of psychotic behavior Describe major indications for the use of

Chapter 18 Drugs Used for Psychoses Learning Objectives Identify signs and symptoms of psychotic behavior Describe major indications for the use of Chapter 18 Drugs Used for Psychoses Learning Objectives Identify signs and symptoms of psychotic behavior Describe major indications for the use of antipsychotic agents Identify common adverse effects

More information

SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT 2 QUALITATIVE AND QUANTITATIVE COMPOSITION

SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT 2 QUALITATIVE AND QUANTITATIVE COMPOSITION SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Driclor Solution 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Aluminium Chloride Hexahydrate 20% w/w For a full list of excipients, see

More information

Thorazine (chlorpromazine)

Thorazine (chlorpromazine) Generic name: Chlorpromazine Available strengths: 10 mg, 25 mg, 50 mg, 100 mg, 200 mg tablets; 100 mg/ml oral concentrate; 25 mg/ml injection Available in generic: Yes Drug class: First-generation (conventional)

More information

Adjunctive psychosocial intervention. Conditions requiring dose reduction. Immediate, peak plasma concentration is reached within 1 hour.

Adjunctive psychosocial intervention. Conditions requiring dose reduction. Immediate, peak plasma concentration is reached within 1 hour. Shared Care Guideline for Prescription and monitoring of Naltrexone Hydrochloride in alcohol dependence Author(s)/Originator(s): (please state author name and department) Dr Daly - Consultant Psychiatrist,

More information

NEUROTONE THR 00904/0005 UKPAR

NEUROTONE THR 00904/0005 UKPAR NEUROTONE THR 00904/0005 UKPAR TABLE OF CONTENTS Lay summary Page 2 Scientific discussion Page 3 Steps taken for assessment Page 10 Summary of Product Characteristics Page 11 Product Information Leaflet

More information

Glycopyrronium Bromide 0.5mg/mL and Neostigmine Metilsulfate 2.5mg/mL Solution for Injection

Glycopyrronium Bromide 0.5mg/mL and Neostigmine Metilsulfate 2.5mg/mL Solution for Injection NEW ZEALAND DATA SHEET Glycopyrronium Bromide 0.5mg/mL and Neostigmine Metilsulfate 2.5mg/mL Solution for Injection Each 1mL contains Glycopyrrolate USP 0.5mg (Glycopyrronium Bromide) and Neostigmine Metilsulfate

More information

Trihexyphenidyl Hydrochloride Oral Solution USP 2 mg per 5 ml

Trihexyphenidyl Hydrochloride Oral Solution USP 2 mg per 5 ml Trihexyphenidyl Hydrochloride Oral Solution USP 2 mg per 5 ml Rx ONLY DESCRIPTION Trihexyphenidyl Hydrochloride Oral Solution USP is a synthetic antispasmodic drug. It is designated chemically as α-cyclohexylα-phenyl-1-piperidinepropanol

More information

PRESCRIBING INFORMATION. (pentazocine hydrochloride tablets) 50 mg. Narcotic Analgesic. 2905 Place Louis R.-Renaud March 26, 2014 Laval, QC H7V 0A3

PRESCRIBING INFORMATION. (pentazocine hydrochloride tablets) 50 mg. Narcotic Analgesic. 2905 Place Louis R.-Renaud March 26, 2014 Laval, QC H7V 0A3 PRESCRIBING INFORMATION N TALWIN TABLETS (pentazocine hydrochloride tablets) 50 mg Narcotic Analgesic sanofi-aventis Canada Inc. Date of Revision: 2905 Place Louis R.-Renaud March 26, 2014 Laval, QC H7V

More information

PHOSPHATE-SANDOZ Tablets (High dose phosphate supplement)

PHOSPHATE-SANDOZ Tablets (High dose phosphate supplement) 1 PHOSPHATE-SANDOZ Tablets (High dose phosphate supplement) PHOSPHATE-SANDOZ PHOSPHATE-SANDOZ Tablets are a high dose phosphate supplement containing sodium phosphate monobasic. The CAS registry number

More information

NEW ZEALAND DATA SHEET NAPHCON-A Naphazoline hydrochloride and pheniramine maleate.

NEW ZEALAND DATA SHEET NAPHCON-A Naphazoline hydrochloride and pheniramine maleate. NEW ZEALAND DATA SHEET NAPHCON-A Naphazoline hydrochloride and pheniramine maleate. PRESENTATION Eye Drops: NAPHCON-A Eye Drops are a combination of an antihistamine (pheniramine maleate) and a decongestant

More information

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Cephacare Flavour 250 mg Tablets for Dogs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains: Active substance:

More information

PRODUCT INFORMATION. Benadryl* for the Family Dry Cough and Nasal Congestion Oral Liquid

PRODUCT INFORMATION. Benadryl* for the Family Dry Cough and Nasal Congestion Oral Liquid PRODUCT INFORMATION Benadryl* for the Family Dry Cough and Nasal Congestion Oral Liquid Product description Each 5 ml of Benadryl* for the Family Dry Cough and Nasal Congestion oral liquid contains dextromethorphan

More information

SR 5. W2364A_NT.XATRAL SR5 PAK/SA 5/12/05 9:47 Page 1

SR 5. W2364A_NT.XATRAL SR5 PAK/SA 5/12/05 9:47 Page 1 W2364A_NT.XATRAL SR5 PAK/SA 5/12/05 9:47 Page 1 alfuzosin SR 5 mg (Alfuzosin HCI) COMPOSITION Each sustained-release, film-coated tablet contains: Alfuzosin hydrochloride......... 5 mg Excipients... q.s.

More information

PHENERGAN VS. ZOFRAN ~Protocol update. A SPECIAL thank you for helping this project get completed: Evans Mutua, SN4 Jill Schrader, NREMT-P, SN4

PHENERGAN VS. ZOFRAN ~Protocol update. A SPECIAL thank you for helping this project get completed: Evans Mutua, SN4 Jill Schrader, NREMT-P, SN4 PHENERGAN VS. ZOFRAN ~Protocol update. A SPECIAL thank you for helping this project get completed: Evans Mutua, SN4 Jill Schrader, NREMT-P, SN4 To complete for Continuing Education Go thru the powerpoint

More information

Public Assessment Report. Table of Contents

Public Assessment Report. Table of Contents Public Assessment Report Lidocaine Injection BP with preservative 1% Lidocaine Injection BP with preservative 2% PL 01502/0070 PL 01502/0071 Hameln Pharmaceuticals Limited Table of Contents Page Lay Summary

More information

For more information concerning patients under 18 years of age, see section Dosage and method of administration.

For more information concerning patients under 18 years of age, see section Dosage and method of administration. Proposed Core Safety Profile (CSP) Active substance: Lormetazepam Date: 16 Oct 2012 Procedure: AT/H/PSUR/0030/001 4.3 Contraindications - Myasthenia gravis - Severe respiratory insufficiency (e.g. severe

More information

Summary of the risk management plan (RMP) for Aripiprazole Pharmathen (aripiprazole)

Summary of the risk management plan (RMP) for Aripiprazole Pharmathen (aripiprazole) EMA/303592/2015 Summary of the risk management plan (RMP) for Aripiprazole Pharmathen (aripiprazole) This is a summary of the risk management plan (RMP) for Aripiprazole Pharmathen, which details the measures

More information

Draft presentation: Summary of product characteristics

Draft presentation: Summary of product characteristics Draft presentation: Summary of product characteristics What is it and what does it contain? Olayinka Fasanya Medical information - Information compliance and consistency An agency of the European Union

More information

Background. Population/Intervention(s)/Comparator/Outcome(s) (PICO)

Background. Population/Intervention(s)/Comparator/Outcome(s) (PICO) updated 2012 Role of anticholinergic medications in patients requiring long-term antipsychotic treatment for psychotic disorders Q6: In individuals with psychotic disorders (including schizophrenia) who

More information

SODIUM CHLORIDE 0.9% W/V SOLUTION FOR INJECTION PL 01502/0068 UKPAR TABLE OF CONTENTS

SODIUM CHLORIDE 0.9% W/V SOLUTION FOR INJECTION PL 01502/0068 UKPAR TABLE OF CONTENTS SODIUM CHLORIDE 0.9% W/V SOLUTION FOR INJECTION PL 01502/0068 UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific discussion Page 3 Steps taken for assessment Page 10 Steps taken after authorisation

More information

SUMMARY OF PRODUCT CHARACTERISTICS. One gram of suspension contains 10 mg fusidic acid (as hemihydrate).

SUMMARY OF PRODUCT CHARACTERISTICS. One gram of suspension contains 10 mg fusidic acid (as hemihydrate). SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Fucithalmic 10 mg/g eye drops, suspension 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One gram of suspension contains 10 mg fusidic acid

More information

Package leaflet : information for the user. Dilute Adrenaline/Epinephrine Injection 1:10,000 adrenaline (epinephrine) (as acid tartrate) 0.

Package leaflet : information for the user. Dilute Adrenaline/Epinephrine Injection 1:10,000 adrenaline (epinephrine) (as acid tartrate) 0. Package leaflet : information for the user Dilute Adrenaline/Epinephrine Injection 1:10,000 adrenaline (epinephrine) (as acid tartrate) 0.1mg per ml Because of your condition it may not be possible for

More information

DEXTROMETHORPHAN HYDROBROMIDE 10MG/5ML ORAL SOLUTION PL 17907/0314

DEXTROMETHORPHAN HYDROBROMIDE 10MG/5ML ORAL SOLUTION PL 17907/0314 DEXTROMETHORPHAN HYDROBROMIDE 10MG/5ML ORAL SOLUTION PL 17907/0314 UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific discussion Page 3 Steps taken for assessment Page 10 Summary of Product Characteristics

More information

Valoid 50 mg Tablets (cyclizine hydrochloride)

Valoid 50 mg Tablets (cyclizine hydrochloride) IRL 075-3236-APIL 28032354 Package leaflet: Information for the patient Valoid 50 mg Tablets (cyclizine hydrochloride) Read all of this leaflet carefully before you start taking this medicine because it

More information

PHENYLEPHRINE HYDROCHLORIDE INJECTION USP

PHENYLEPHRINE HYDROCHLORIDE INJECTION USP PRESCRIBING INFORMATION PHENYLEPHRINE HYDROCHLORIDE INJECTION USP 10 mg/ml Sandoz Canada Inc. Date of Preparation: September 1992 145 Jules-Léger Date of Revision : January 13, 2011 Boucherville, QC, Canada

More information

Hypromellose Eye Drops BP 0.3% w/v PL 23097/0006

Hypromellose Eye Drops BP 0.3% w/v PL 23097/0006 Hypromellose Eye Drops BP 0.3% w/v PL 23097/0006 UKPAR TABLE OF CONTENTS Lay summary Page 2 Scientific discussion Page 3 Steps taken for assessment Page 9 Summary of product characteristics Page 10 Patient

More information

Naltrexone Shared Care Guideline for the treatment of alcohol dependence and opioid dependance

Naltrexone Shared Care Guideline for the treatment of alcohol dependence and opioid dependance Naltrexone Shared Care Guideline for the treatment of alcohol dependence and opioid dependance Introduction Indication/Licensing information: Naltrexone is licensed for use as an additional therapy, within

More information

CENTRAL NERVOUS SYSTEM MANAGEMENT OF PARKINSON S DISEASE

CENTRAL NERVOUS SYSTEM MANAGEMENT OF PARKINSON S DISEASE MANAGEMENT CENTRAL NERVOUS SYSTEM MANAGEMENT OF PARKINSON S DISEASE Parkinson s Disease is classically determined by the triad or rest tremor (usually starting in one arm) with bradykinesia (slowing of

More information

Information for Prescribing Anti-dementia Drugs. November 2012

Information for Prescribing Anti-dementia Drugs. November 2012 Information for Prescribing Anti-dementia Drugs The aim of this document is to provide information about the prescribing of anti-dementia medication for adult patients with dementia following an assessment

More information

Product Summary. 1. Name of the Medicinal Product. Dehydrated Alcohol (Absolute Alcohol) BP for Injection. 2. Qualitative and Quantitative Composition

Product Summary. 1. Name of the Medicinal Product. Dehydrated Alcohol (Absolute Alcohol) BP for Injection. 2. Qualitative and Quantitative Composition Product Summary 1. Name of the Medicinal Product Dehydrated Alcohol (Absolute Alcohol) BP for Injection 2. Qualitative and Quantitative Composition Ethanol BP 100% v/v 3. Pharmaceutical Form Solution for

More information

Doncaster & Bassetlaw Medicines Formulary

Doncaster & Bassetlaw Medicines Formulary Doncaster & Bassetlaw Medicines Formulary Section 4.9: Drugs Used in Parkinsonism and related Disorders Co-Beneldopa 12.5/50, 25/100 and 50/200 (Madopar) Capsules Co-Beneldopa 12.5/50 and 25/100 Dispersible

More information

For the use only of a Registered Medical Practitioner or a Hospital or a Laboratory EMODERM CREAM. White Soft Paraffin Cream

For the use only of a Registered Medical Practitioner or a Hospital or a Laboratory EMODERM CREAM. White Soft Paraffin Cream For the use only of a Registered Medical Practitioner or a Hospital or a Laboratory EMODERM CREAM White Soft Paraffin Cream QUALITATIVE AND QUANTITATIVE COMPOSITION Emollient Cream base of White Soft Paraffin

More information

SUMMARY OF PRODUCT CHARACTERISTICS. 1. NAME OF THE MEDICINAL PRODUCT DARROW 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Active ingredients:

SUMMARY OF PRODUCT CHARACTERISTICS. 1. NAME OF THE MEDICINAL PRODUCT DARROW 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Active ingredients: SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT DARROW 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Active ingredients: Sodium chloride - 4.0 g/l Sodium lactate - 5.9 g/l Potassium chloride

More information

Package Insert. Product Summary. 1. Name of the medicinal product

Package Insert. Product Summary. 1. Name of the medicinal product Package Insert Renerve Injection Product Summary 1. Name of the medicinal product Renerve Injection 2. Qualitative and quantitative composition Each 1 ml contains: Mecobalamin I.P. 1000 mcg. 3. Pharmaceutical

More information

Medicines to Treat Cough & Cold

Medicines to Treat Cough & Cold Zytrec-D (contains pseudoephredrine & cetirizine) Clarinase (contains loratidine & pseudoephredrine) For adults and children 12 years old and above: Take 1 tablet twice a day Clarinase repetab: For adults

More information

SYMMETREL (amantadine hydrochloride)

SYMMETREL (amantadine hydrochloride) 1 SYMMETREL (amantadine hydrochloride) NAME OF THE MEDICINE Active ingredient: amantadine hydrochloride. Chemical name: 1-adamantanamine hydrochloride CAS number; 665-67-7 Molecular weight: 187.71 Molecular

More information

VALIUM PRODUCT MONOGRAPH. diazepam. 5 mg Tablets. Anxiolytic-sedative. Date of Revision: February 7, 2014

VALIUM PRODUCT MONOGRAPH. diazepam. 5 mg Tablets. Anxiolytic-sedative. Date of Revision: February 7, 2014 PRODUCT MONOGRAPH VALIUM diazepam 5 mg Tablets Anxiolytic-sedative Hoffmann-La Roche Ltd. 7070 Mississauga Road Mississauga, Ontario L5N 5M8 Date of Revision: February 7, 2014 www.rochecanada.com Submission

More information

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Prednicare Tablets 5mg 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains: Active Substance(s) Prednisolone

More information

Summary of Product Characteristics

Summary of Product Characteristics Summary of Product Characteristics 1 NAME OF THE VETERINARY MEDICINAL PRODUCT ACEGON, 50 microgram/ml, solution for injection for cattle. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml contains: Active

More information

Diazepam 2 mg and 5 mg tablets This product may not be interchangeable with similar products on the New Zealand market

Diazepam 2 mg and 5 mg tablets This product may not be interchangeable with similar products on the New Zealand market Arrow - Diazepam Diazepam 2 mg and 5 mg tablets This product may not be interchangeable with similar products on the New Zealand market Presentation Arrow - Diazepam 2 White, round, flat-bevel edged tablet

More information

Public Assessment Report

Public Assessment Report Public Assessment Report SoLo Prep PL 11847/0013 MHRA: PAR SoLo Prep PL 11847/0013 1 SOLO PREP PL 11847/0013 UKPAR TABLE OF CONTENTS Page Lay Summary 3 Scientific discussion 4 Steps taken for assessment

More information

Trama Injection Solution for Injection

Trama Injection Solution for Injection Insert Leaflet Trama Injection Solution for Injection Composition Active substance Each 2 ml ampoule contains 100 mg tramadol hydrochloride. Inactive substances Sodium acetate, water for injection. Therapeutic

More information

0.9% Sodium Chloride Intravenous Infusion Solution

0.9% Sodium Chloride Intravenous Infusion Solution 1. NAME OF THE MEDICINAL PRODUCT 0.9% Sodium Chloride Intravenous Infusion Solution 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Sodium Chloride 9g per litre. For a full list of excipients, see section

More information

N-methyl-D-aspartate (NMDA) Receptor Antagonist Memantine (CWM TAF ONLY)

N-methyl-D-aspartate (NMDA) Receptor Antagonist Memantine (CWM TAF ONLY) Bro Taf Localities Drugs & Therapeutics Committee SHARED CARE Drugs: Acetylcholinesterase inhibitors - Donepezil, Rivastigmine and Galantamine (Cardiff and Vale and Cwm Taf) Protocol No. CV 52 N-methyl-D-aspartate

More information

PACKAGE LEAFLET: INFORMATION FOR THE USER. ADRENALINE (TARTRATE) STEROP 1 mg/1 ml Solution for injection. Adrenaline (Levorenine, Epinephrine)

PACKAGE LEAFLET: INFORMATION FOR THE USER. ADRENALINE (TARTRATE) STEROP 1 mg/1 ml Solution for injection. Adrenaline (Levorenine, Epinephrine) PACKAGE LEAFLET: INFORMATION FOR THE USER ADRENALINE (TARTRATE) STEROP 1 mg/1 ml Solution for injection Adrenaline (Levorenine, Epinephrine) Read all of this leaflet carefully before you start using this

More information

Summary of Product Characteristics Medical Helium

Summary of Product Characteristics Medical Helium Summary of Product Characteristics Medical Helium www.uk.airliquide.com 1. NAME OF THE MEDICINAL PRODUCT Medical Helium 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Helium BP 1988 100%. 3. PHARMACEUTICAL

More information

COMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) FINAL COMMUNITY HERBAL MONOGRAPH ON HYPERICUM PERFORATUM L., HERBA (TRADITIONAL USE)

COMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) FINAL COMMUNITY HERBAL MONOGRAPH ON HYPERICUM PERFORATUM L., HERBA (TRADITIONAL USE) European Medicines Agency Evaluation of Medicines for Human Use London, 12 November 2009 Doc. Ref.: EMEA/HMPC/745582/2009 COMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) FINAL COMMUNITY HERBAL MONOGRAPH

More information

Thioctacid 600 T Solution for Injection contains 600 mg alpha-lipoic acid

Thioctacid 600 T Solution for Injection contains 600 mg alpha-lipoic acid Package Leaflet: Information for the User Thioctacid 600 T Solution for Injection contains 600 mg alpha-lipoic acid For use in adults Active substance: Alpha-lipoic acid, Trometamol salt (1:1) Read all

More information

Guidance on initiating the Prescribing of Donepezil in Primary Care

Guidance on initiating the Prescribing of Donepezil in Primary Care Guidance on initiating the Prescribing of Donepezil in Primary Care 1st edi(on, September 2013 Introduction This guidance has been commissioned by the Strategic Clinical Network for Mental Health, Dementia,

More information

Psychotherapeutic and Anti-Parkinson Drugs

Psychotherapeutic and Anti-Parkinson Drugs 1 Unit 14 Psychotherapeutic and Anti-Parkinson Drugs 2 Drugs for Psychoses Most psychoses have no identifiable cause and require long-term drug therapy 3 Signs and Symptoms Delusions (strong beliefs in

More information

Low dose naltrexone as a treatment for multiple sclerosis

Low dose naltrexone as a treatment for multiple sclerosis Low dose naltrexone as a treatment for multiple sclerosis Can I take study demonstrated that naltrexone The low dose naltrexone as a treatment for multiple sclerosis should be of naltrexone is microcrystalline

More information

CODEINE PHOSPHATE 15 MG TABLETS CODEINE PHOSPHATE 30 MG TABLETS CODEINE PHOSPHATE 60 MG TABLETS PL 24837/0023-5 UK PAR TABLE OF CONTENTS

CODEINE PHOSPHATE 15 MG TABLETS CODEINE PHOSPHATE 30 MG TABLETS CODEINE PHOSPHATE 60 MG TABLETS PL 24837/0023-5 UK PAR TABLE OF CONTENTS CODEINE PHOSPHATE 15 MG TABLETS CODEINE PHOSPHATE 30 MG TABLETS CODEINE PHOSPHATE 60 MG TABLETS PL 24837/0023-5 UK PAR TABLE OF CONTENTS Lay Summary Page 2 Scientific discussion Page 3 Steps taken for

More information

Paxil/Paxil-CR (paroxetine)

Paxil/Paxil-CR (paroxetine) Generic name: Paroxetine Available strengths: 10 mg, 20 mg, 30 mg, 40 mg tablets; 10 mg/5 ml oral suspension; 12.5 mg, 25 mg, 37.5 mg controlled-release tablets (Paxil-CR) Available in generic: Yes, except

More information

COMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) FINAL COMMUNITY HERBAL MONOGRAPH ON HYPERICUM PERFORATUM L., HERBA (WELL-ESTABLISHED MEDICINAL USE)

COMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) FINAL COMMUNITY HERBAL MONOGRAPH ON HYPERICUM PERFORATUM L., HERBA (WELL-ESTABLISHED MEDICINAL USE) European Medicines Agency Evaluation of Medicines for Human Use London, 12 November 2009 Doc. Ref.: EMA/HMPC/101304/2008 COMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) FINAL COMMUNITY HERBAL MONOGRAPH ON

More information

SANOMIGRAN Elixir (pizotifen)

SANOMIGRAN Elixir (pizotifen) SANOMIGRAN Elixir (pizotifen) Patient Information Leaflet What you need to know about Sanomigran Elixir Your doctor has decided that you need this medicine to help treat your condition. Please read this

More information

ZOVIRAX Cold Sore Cream

ZOVIRAX Cold Sore Cream Data Sheet ZOVIRAX Cold Sore Cream Aciclovir 5% w/w Presentation Topical cream Indications ZOVIRAX Cold Sore Cream is indicated for the treatment of Herpes simplex virus infections of the lips and face

More information

Doxylamine succinate belongs to the ethanolamine class of antihistamines with sedative properties.

Doxylamine succinate belongs to the ethanolamine class of antihistamines with sedative properties. Data Sheet MERSYNDOL Tablet Paracetamol 450mg per tablet Codeine Phosphate 9.75mg per tablet Doxylamine Succinate 5mg per tablet MERSYNDOL FORTE Tablet Paracetamol 450mg per tablet Codeine Phosphate 30mg

More information

Public Assessment Report. Decentralised Procedure. Alimemazine tartrate 7.5mg/5ml Syrup. Alimemazine tartrate 30mg/5ml Syrup

Public Assessment Report. Decentralised Procedure. Alimemazine tartrate 7.5mg/5ml Syrup. Alimemazine tartrate 30mg/5ml Syrup Public Assessment Report Decentralised Procedure Alimemazine tartrate 7.5mg/5ml Syrup Alimemazine tartrate 30mg/5ml Syrup Procedure No: UK Licence No: PL 41830/0029-0030 NRIM Limited 1 LAY SUMMARY Alimemazine

More information

Acetylcholinesterase Inhibitors and Memantine Clinical Indication: Treatment of Dementia in Alzheimer s Disease (AD)

Acetylcholinesterase Inhibitors and Memantine Clinical Indication: Treatment of Dementia in Alzheimer s Disease (AD) SHARED CARE PROTOCOL AND INFORMATION FOR GPS Acetylcholinesterase Inhibitors and Memantine Clinical Indication: Treatment of Dementia in Alzheimer s Disease (AD) Version: 3 Date Approved: June 2011 Review

More information

Prior Authorization Guideline

Prior Authorization Guideline Prior Authorization Guideline Guideline: CSD - Suboxone Therapeutic Class: Central Nervous System Agents Therapeutic Sub-Class: Analgesics and Antipyretics (Opiate Partial Agonists) Client: County of San

More information

Read all of this leaflet carefully because it contains important information for you.

Read all of this leaflet carefully because it contains important information for you. Package Leaflet: Information for the User Thioctacid 600 HR, Film-coated tablets For use in adults Active substance: Alpha-lipoic acid Read all of this leaflet carefully because it contains important information

More information

VI.2 Elements for a Public Summary

VI.2 Elements for a Public Summary VI.2 Elements for a Public Summary VI.2.1 Overview of disease epidemiology Bipolar I Disorder Reported prevalence rates for bipolar I disorder differ due to local variations in psychiatric practice, variations

More information

Salbutamol 1mg/ml Nebuliser Solution. Salbutamol 2mg/ml Nebuliser Solution PL 36390/0035 PL 36390/0036

Salbutamol 1mg/ml Nebuliser Solution. Salbutamol 2mg/ml Nebuliser Solution PL 36390/0035 PL 36390/0036 Salbutamol 1mg/ml Nebuliser Solution Salbutamol 2mg/ml Nebuliser Solution PL 36390/0035 PL 36390/0036 UKPAR TABLE OF CONTENTS Lay summary Page 2 Scientific discussion Page 3 Steps taken for assessment

More information

Core Safety Profile. Pharmaceutical form(s)/strength: 50mg tablets IE/H/PSUR/0028/002 Date of FAR: 17.07.2013

Core Safety Profile. Pharmaceutical form(s)/strength: 50mg tablets IE/H/PSUR/0028/002 Date of FAR: 17.07.2013 Core Safety Profile Active substance: Naltrexone Hydrochloride Pharmaceutical form(s)/strength: 50mg tablets P-RMS: IE/H/PSUR/0028/002 Date of FAR: 17.07.2013 4.2 Posology and method of administration

More information

3% Sodium Chloride Injection, USP 5% Sodium Chloride Injection, USP

3% Sodium Chloride Injection, USP 5% Sodium Chloride Injection, USP PRESCRIBING INFORMATION 3% Sodium Chloride Injection, USP 5% Sodium Chloride Injection, USP IV Fluid and Electrolyte Replenisher Baxter Corporation Mississauga, Ontario L5N 0C2 Canada Date of Revision:

More information

PRODUCT INFORMATION. MYDRIACYL (Tropicamide) 0.5% and 1.0% Eye Drops NAME OF THE MEDICINE

PRODUCT INFORMATION. MYDRIACYL (Tropicamide) 0.5% and 1.0% Eye Drops NAME OF THE MEDICINE NAME OF THE MEDICINE PRODUCT INFORMATION MYDRIACYL (Tropicamide) 0.5% and 1.0% Eye Drops The active ingredient in MYDRIACYL Eye Drops is tropicamide or (2RS) N-ethyl-3- hydroxy-2-phenyl-n- (pyrid-4-ylmethyl)

More information

SHARED CARE GUIDELINE

SHARED CARE GUIDELINE SHARED CARE GUIDELINE Title: Lithium treatment in adults aged 65 years and over Scope: Pennine Care NHS Foundation Trust NHS Bury NHS Oldham NHS Heywood, Middleton and Rochdale NHS Stockport NHS Tameside

More information

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Calvepen 333 and 666 mg Tablets. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Calvepen 333 mg Tablets: Each tablet contains 333mg of Phenoxymethylpenicillin

More information

Contemporary Psychiatric-Mental Health Nursing. Assessing the Effectiveness of Medications. Administering Medications

Contemporary Psychiatric-Mental Health Nursing. Assessing the Effectiveness of Medications. Administering Medications Contemporary Psychiatric-Mental Health Nursing Chapter 32 Psychopharmacologic Nursing Interventions Assessing the Effectiveness of Medications Include how well the medications are helping the client to

More information

Summary of Product Characteristics Medical Air

Summary of Product Characteristics Medical Air Summary of Product Characteristics Medical Air www.uk.airliquide.com 1. NAME OF THE MEDICINAL PRODUCT Medical Air 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Air Ph.Eur. 100% 3. PHARMACEUTICAL FORM Inhalation

More information

Elements for a public summary. VI.2.1 Overview of disease epidemiology. VI.2.2 Summary of treatment benefits

Elements for a public summary. VI.2.1 Overview of disease epidemiology. VI.2.2 Summary of treatment benefits VI.2 Elements for a public summary VI.2.1 Overview of disease epidemiology Pain is one of the most common reasons for a patient to seek medical attention. Moderate or severe intensity pain can be acute

More information

ISOPLEX 4% W/V SOLUTION FOR INFUSION (Succinylated gelatin) PL 13538/0017 UKPAR TABLE OF CONTENTS

ISOPLEX 4% W/V SOLUTION FOR INFUSION (Succinylated gelatin) PL 13538/0017 UKPAR TABLE OF CONTENTS ISOPLEX 4% W/V SOLUTION FOR INFUSION (Succinylated gelatin) PL 13538/0017 UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific discussion Page 3 Steps taken for assessment Page 11 Steps taken after authorisation

More information

Irish Medicines Board

Irish Medicines Board IRISH MEDICINES BOARD ACT 1995 EUROPEAN COMMUNITIES (ANIMAL REMEDIES) (No. 2) REGULATIONS 2007 (S.I. No. 786 of 2007) VPA: 10834/001/003 Case No: 7006279 The Irish Medicines Board in exercise of the powers

More information

Nursing 113. Pharmacology Principles

Nursing 113. Pharmacology Principles Nursing 113 Pharmacology Principles 1. The study of how drugs enter the body, reach the site of action, and are removed from the body is called a. pharmacotherapeutics b. pharmacology c. pharmacodynamics

More information

Donepezil (Aricept ), Galantamine (Reminyl XL ), Rivastigmine (Exelon ) and Memantine (Ebixa )

Donepezil (Aricept ), Galantamine (Reminyl XL ), Rivastigmine (Exelon ) and Memantine (Ebixa ) Donepezil (Aricept ), Galantamine (Reminyl XL ), Rivastigmine (Exelon ) and Memantine (Ebixa ) ESCA: For the treatment of Alzheimer s disease. SECONDARY CARE SECTION TO BE COMPLETED BY INITIATING DOCTOR

More information

European Medicines Agency recommends restricting use of trimetazidine-containing medicines

European Medicines Agency recommends restricting use of trimetazidine-containing medicines 22 June 2012 EMA/CHMP/417861/2012 Press Office Press release European Medicines Agency recommends restricting use of trimetazidine-containing medicines Restricted indication for patients with stable angina

More information

MOH CLINICAL PRACTICE GUIDELINES 2/2008 Prescribing of Benzodiazepines

MOH CLINICAL PRACTICE GUIDELINES 2/2008 Prescribing of Benzodiazepines MOH CLINICL PRCTICE GUIELINES 2/2008 Prescribing of Benzodiazepines College of Family Physicians, Singapore cademy of Medicine, Singapore Executive summary of recommendations etails of recommendations

More information

Below, this letter outlines [patient name] s medical history, prognosis, and treatment rationale.

Below, this letter outlines [patient name] s medical history, prognosis, and treatment rationale. [Date] [Name of Contact] [Title] [Name of Health Insurance Company] [Address] [City, State, Zip Code] Insured: [Patient Name] Policy Number: [Number] Group Number: [Number] Diagnosis: [Diagnosis and ICD-9-CM

More information

Summary of Product Characteristics

Summary of Product Characteristics 1 NAME OF THE MEDICINAL PRODUCT Trimega 1000 mg Capsules Summary of Product Characteristics 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each capsule contains 1000 mg Omega-3-acid ethyl esters 90, comprising

More information

Core Safety Profile. Pharmaceutical form(s)/strength: Nasal suspension, 50mcg UK/H/PSUR/0041/001 Date of FAR:

Core Safety Profile. Pharmaceutical form(s)/strength: Nasal suspension, 50mcg UK/H/PSUR/0041/001 Date of FAR: Core Safety Profile Active substance: Mometasone Pharmaceutical form(s)/strength: Nasal suspension, 50mcg P-RMS: UK/H/PSUR/0041/001 Date of FAR: 17.06.2010 4.3 Contraindications / / (mometasone furoate)

More information

MEDICATION GUIDE. Tranxene* (TRAN-zeen) T-TAB (clorazepate dipotassium) tablets

MEDICATION GUIDE. Tranxene* (TRAN-zeen) T-TAB (clorazepate dipotassium) tablets MEDICATION GUIDE Tranxene* (TRAN-zeen) T-TAB (clorazepate dipotassium) tablets Read this Medication Guide before you start taking TRANXENE and each time you get a refill. There may be new information.

More information

Naloxone Hydrochloride Injection PRODUCT INFORMATION

Naloxone Hydrochloride Injection PRODUCT INFORMATION Naloxone Hydrochloride Injection PRODUCT INFORMATION DESCRIPTION Naloxone hydrochloride is 17-allyl-4,5α-epoxy-3,14-dihydroxymorphinan-6-one hydrochloride; C 19 H 21 NO 4.HCl. It is an off-white powder

More information

PARACETAMOL REXIDOL. 600 mg Tablet. Analgesic-Antipyretic. Paracetamol 600 mg

PARACETAMOL REXIDOL. 600 mg Tablet. Analgesic-Antipyretic. Paracetamol 600 mg (Insert Text) UL Consumer Health PARACETAMOL REXIDOL 600 mg Tablet Analgesic-Antipyretic FORMULATION Each tablet contains: Paracetamol 600 mg PRODUCT DESCRIPTION Rexidol is a round, yellow, flat, bevel-edged

More information

Share the important information in this Medication Guide with members of your household.

Share the important information in this Medication Guide with members of your household. MEDICATION GUIDE BUPRENORPHINE (BUE-pre-NOR-feen) Sublingual Tablets, CIII IMPORTANT: Keep buprenorphine sublingual tablets in a secure place away from children. Accidental use by a child is a medical

More information

TALWIN Nx CIV pentazocine and naloxone hydrochlorides, USP Analgesic for Oral Use Only

TALWIN Nx CIV pentazocine and naloxone hydrochlorides, USP Analgesic for Oral Use Only TALWIN Nx CIV pentazocine and naloxone hydrochlorides, USP Analgesic for Oral Use Only TALWIN Nx is intended for oral use only. Severe, potentially lethal, reactions may result from misuse of TALWIN Nx

More information

MEDGUIDE SECTION. What is the most important information I should know about SEROQUEL? SEROQUEL may cause serious side effects, including:

MEDGUIDE SECTION. What is the most important information I should know about SEROQUEL? SEROQUEL may cause serious side effects, including: MEDGUIDE SECTION Medication Guide SEROQUEL (SER-oh-kwell) (quetiapine fumarate) Tablets Read this Medication Guide before you start taking SEROQUEL and each time you get a refill. There may be new information.

More information

One vial contains 500 U* of C1-inhibitor** After reconstitution the product contains 500 U/5 ml which correspond to a concentration of 100 U/ml.

One vial contains 500 U* of C1-inhibitor** After reconstitution the product contains 500 U/5 ml which correspond to a concentration of 100 U/ml. SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Cetor 100 U/ml powder and solvent for solution for injection 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One vial contains 500 U* of

More information